Newer drugs like Enbrel and Remicade have been a boon to many arthritis sufferers but recent research has shown that such drugs can lead to the development of an inflammatory disorder of blood vessels, usually affecting the skin. The drugs, called TNF (tumor necrosis factor) blockers, have been linked to a condition called leukocytoclastic vasculitis, or LCV. With LCV, bleeding of small blood vessels under the skin causes purplish raised areas to appear, usually on the legs. LCV has been described as a manifestation of rheumatoid arthritis itself, but the latest findings suggests that it may occur as an adverse effect of anti-TNF therapy as well. Researchers from the Research Institute in Sioux Falls, South Dakota, examined reports collected by the US Food and Drug Administration about adverse events associated with the use of TNF blockers. They identified 20 cases of LCV following Enbrel treatment and 15 following Remicade use. While the drugs can be used to treat other conditions, rheumatoid arthritis was the most common among these cases. All but six of the patients were women. In total, 22 of the patients showed complete or marked improvement of their skin lesions when they stopped taking the agents. Three patients on Enbrel had continuing lesions despite discontinuation of the drug. One improved after switching to Remicade, but another subject on Remicade had continuing lesions despite discontinued treatment. Six patients had a recurrence of LCV when they re-started TNF blocker therapy, but three patients did not have recurrence of their skin lesions following rechallenge with the same agents. The researchers concluded that these drugs are so beneficial that the risk of developing easily reversible vasculitis should not generally discourage their use.
Journal of Rheumatology,
October 2004